Digital health innovations
We are actively seeking proven digital innovations that improve the health of people in the region and raise the quality, efficiency, safety and cost-effectiveness of delivering healthcare.
We are particularly interested to hear about innovations in the following categories:
  • Health maintenance - supporting people in maintaining their physical and mental wellbeing,
  • Prevention - alerting patients, carers or professionals when there are signs that things aren’t going well, and an intervention can prevent crises or emergencies
  • Access - providing more convenient and cost-effective ways for patients and professionals to interact. (e.g. remote monitoring or virtual consultations).
  • Learning and education - delivering information and knowledge to patients about their health or condition, or to professionals to support their continuous professional development
  • Pathways - providing tailored information to patients, carers and professionals on services to signpost people to the most appropriate place.  Ideally, this could be enhanced with real-time information about capacity.
  • Research - using digital tools to promote involvement in research & clinical trials, to streamline the capture of informed consent, and to capture research data more efficiently and conveniently.
  • Integration - tools that enable the secure, appropriate sharing of information between organisations (e.g. GPs and hospital clinicians) and sectors (e.g. NHS and Social Services) to allow patients to receive seamless care.
  • Data Visualisation - innovative ways of presenting information in a meaningful way to enable more informed decisions by patients and professionals.  This may involve aggregating data from different sources, reporting tools or graphic visualisations such as heat maps.

Ideas (Advanced diagnostics, genomics and precision medicine)

Innovation 'Elevator Pitch':
Modul-Bio provides a biological data management software specifically designed for biobanks and cohort projects. Main functionalities include patient management, samples collection, processing, distribution and disposal.
Overview of Innovation:
MBioLIMS BioBanking®
 
Modul-Bio solutions allow users to manage the complete lifecycle of biological material and related data. MBioLIMS BioBanking® is dedicated to the management of samples and associated data and is modular and evolutive allowing the expansion and fit of the system to match laboratory requirements..
The whole system is intuitive for end-users, flexible for customization, easily scalable even in a multi-site environment, accepts plug-ins for applications or equipment such as laboratory instruments, robotics or storage, and ensures long term data security.

Access to the application is via a local Browser with no installation required on individual computers. The setup of the system facilitates confidentiality with secured data transmission on HTTPS, and is VPN compatible. MBioLIMS BioBanking® can be installed locally, or as a cloud solution to fit client needs.

It is possible to specify the level of access of each user by creating new profiles with specific roles. It is also possible to show/hide nominative data. Each site can have an internal administrator, trained by Modul-Bio’s team to manage and evolve the solution as required.

A complete Audit Trail is embedded within MBioLIMS BioBanking® which records all actions taken including user registration, who performed the action (create, modify, delete), date and time, fields and values that have been modified. This covers sample movement, transformation to end points such as destruction to provide traceability and information that can be used in reports, audits and business improvement.

Sample storage and movement is fully monitored and storage containers can be designed and edited by system administrators. This allows the client to replicate the laboratory space within the system, monitor and report sample movement and custody. Storage can be assigned to certain studies, or restricted to particular sample types to prevent incorrect use of space. If samples are transferred to other facilities, or external contacts the shipment and manifests of these activities can also be created and controlled within the application. The interface provides a visual representation of the storage system that allows users to navigate all freezers, nitrogen tanks as well as their content all the way to the details of the sample container (tube/plate/2D rack, etc.)

Many other modules are available, and more are developed each year to match biobank requirements.
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Advanced diagnostics, genomics and precision medicine / Clinical trials and evidence / Digital health / Innovation and adoption
Benefit to NHS:
MbioLIMS provides a specific solution for biobanking laboratories and projects. This facilitates the management of the patient and sample data, and generates viable sample / metadata for research. It can also be connected to eMBIOBANK, a web catalogue for research use.
NHS data can be stored securely, or held outside of the MbioLIMS application and linked by an anoymous unique identifier. In either case, samples and derivatives are linked to the information required.
Initial Review Rating
3.40 (1 ratings)
Benefit to WM population:
Modul-Bio is commited to providing a benefit to all client locations, but has resource locally to the West Midlands.
Current and planned activity: 
MbioLIMS is already used in the UK, with NHS data integration as needed. Modul-Bio is continuing to expand both UK and International clients with the required connection to patient registeries.
The application is designed to improve biobank management, sample custody and viability to promote more utilisation and research for increasing patient well being.
What is the intellectual property status of your innovation?:
The Software and any authorized copy are the intellectual property, the valuable trade secrets and confidential information of the Service Provider who owns the relevant rights. The Software is protected by law, including without limitation the copyright laws of France and other countries, and by international treaty provisions. The Service Provider does not assign any property right when licensing its software solutions and reserves all rights not herein granted. 
Return on Investment (£ Value): 
high
Return on Investment (Timescale): 
6-12 mon
Ease of scalability: 
Simple
Regional Scalability:
MBioLIMS has an available compartmentalisation module which is designed for scalability across regions (or even countries) so that different laboratories can access the same instance when working together.
Modul-Bio has previously implemented solutions within the same regions and once inbedded can facilitate user groups and collaboration.
Measures:
Modul-Bio has designed MBioLIMS to improve biobank processes, sample custody and managment. The system is focused on faster and more thourough management and processing. We do ask current clients for reviews and identified ROI's.
Adoption target:
Target clients are hospitals, universities and private organisations that host a biobank.
 
Read more
Hide details
Mike Woodward 01/07/2019 - 12:27 Detailed Submission Login or Register to post comments
0
0
Votes
-99999
Innovation 'Elevator Pitch':
Amplitude pro enterprise™ uses simple technology to capture clinical and outcome data for specific diseases, diagnosis, interventions and care pathways. Data is retained locally and available for immediate reporting and analysis.
Overview of Innovation:
The Amplitude pro enterprise™ software is a simple, tailored online platform centred around two crucial elements:
A user-friendly electronic patient portal which gives patients the freedom of completing their scores online at home, on site and via various devices and a consultant dashboard giving the clinician(s) the ability to input patient specific complexity factors and procedure data quickly and easily.

The result is representative, accurate and meaningful data that paints a clearer picture of each patient’s level of health and expected recovery. Clinicians are engaged with the clinical outcomes processes at your hospital, you get the insight required to innovate your clinical services and patients get a consistently high standard of care.

pro enterprise™ is simple, cost effective and delivers precise and accurate data, selecting scores that are identified as important to you.

The data you collect in pro enterprise™ will allow you to monitor your service delivery, identify quality issues and demonstrate levels of care. Your hospital can be confidently transparent about its activities, resulting in reassurance to your peers that you are offering the best care possible.

Amplitude specialises in the collection of electronic PROMs and clinical outcomes and we are the leading supplier of electronic PROMs to the NHS. We are accredited by NHS Digital for the electronic capture and upload of National PROMs and our platforms have achieved the highest levels of IG compliance, using data centres that are ISO27001 certified. 

Amplitude's unique data exchange tool means that you enter and retain your data locally in your pro enterprise™ platform and the necessary data for clinical registries, National PROMs and NJR can be  pushed to the relevant databases on your behalf.

Our systems are designed to empower clinicians in adding value to their data e.g. proper case mix adjustment, log-book, revalidation report and easy analysis and self-monitoring tools. The system automates the process of data collection via a series of reminders sent to patients via email and SMS. These reminders are triggered from the intervention data which at minimum includes procedure/intervention description and diagnosis. 

Amplitude pro enterprise™ is customised and tailored to suit specific department requirements and objectives including virtual clinics, clinical outcomes and PROMs. pro enterprise™ is currently being used in T&O, Rheumatology, Urology, Cardiology and Mental Health departments.
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Mental Health: recovery, crisis and prevention / Long term conditions: a whole system, person-centred approach / Advanced diagnostics, genomics and precision medicine / Wellness and prevention of illness / Education, training and future workforce / Clinical trials and evidence / Digital health / Innovation and adoption
Benefit to NHS:
The Amplitude pro enterprise™ system captures and manages clinical and PROM’s outcome data with the key focus to improve overall quality of patient care.
NHS healthcare professionals are required in many specialist areas, to monitor the long-term effects of treatments.  Historically, these were captured on a macro level and this mass gathering of non-specific data, results in outcomes data that is non-meaningful and without sufficient detail or context, preventing its use in making effective, informed clinical and management decisions.
In addition, due to the paper-based nature of how PROM’s and clinical outcomes were historically gathered, often, data would only be made available months after being gathered and in an aggregated and anonymised format, rendering it out of date and of little value.

With Amplitude pro enterprise™, The NHS benefits from the ability to;
  • Capture the clinical outcomes of patients in larger numbers and in an electronic format,
  • Effectively measure the quality of care provided by clinicians in real-time
  • Measure the efficacy of the treatments being used on a local, national and international level
  • Reduce costs associated with carrying out the required questionnaires in a paper format
  • Use the data gathered to compare treatment plans and ensure that patients are receiving the best possible care available
  • Increase clinical and patient compliance and engagement in outcome data collection
  • Meet the challenge to make the NHS paperless
  • Opportunity to provide multiple language options; allowing the patient to complete their electronic questionnaires in their native language instantly
  • Use Amplitude's unique data exchange tool to automatically upload required registry data when the information is gathered in the Amplitude pro registry™ platforms, thus reducing administration, duplication of effort and importantly, retains the outcomes data at the source pro enterprise™ system, allowing instant insight
  • Access to comprehensive reporting tools, that include templated validation reports for individual clinicians, further reducing resource, time and effort
Amplitude pro enterprise™ provides the NHS with a paperless, streamlined data gathering software, that reduces costs, has real-time results, meaningful insights for clinical and managerial decision makers and ultimately improves the overall quality of patient care.
Initial Review Rating
4.80 (2 ratings)
Benefit to WM population:
The West Midlands AHSN covers 6 regions within the NHS; Birmingham and Solihull, The Black Country, Coventry and Warwickshire, Herefordshire and Worcestershire, Shropshire and Staffordshire.

Within this area, there are 33 NHS Trusts servicing the needs of a population of approximately 7.225 million (ONS 2017). According to the ONS, 18.2% of the population were aged 65 years and over.
It is also documented that over half (54%) of older people have at least two chronic conditions increasing to 69% among those aged 85+ (Kingston, et al., 2018).
Multi-morbidity increases the likelihood of hospital admission, length of stay and likelihood of readmission, raises healthcare costs, reduces quality of life, and  increases dependency. (Kingston et al., 2018).

These are all operational factors being faced in the West Midlands region and the implementation of innovative technologies, to help manage the growing dependency on the NHS, are essential.
The implementation of Amplitude pro enterprise™ will not only allow for monitoring outcomes, it can also use the outcomes data to manage workloads, triage clinics and help to influence operational management. 

Eg; fracture clinics see all patients admitted to A&E with musculoskeletal problems, the system could reduce the number of follow up appointments in Trauma and Orthopaedics clinics by assessing cases in a virtual clinic, prioritising the appointments of patients that require surgery or a clinic appointment and booking those that are less urgent into follow up clinics.

Or: The Amplitude pro enterprise™ platform can provide the method of prioritising more urgent cases in Rheumatology or Cardiology clinics, allowing urgent cases to be seen ahead of patients who are performing well with their current ongoing treatment plan.

Managing the patients according to need and not by pre-set time frames, could help to prevent potential A&E visits by patients who deteriorate or do not respond as expected to their treatment plans.

Administrative workloads can be reduced, and the overall quality of care provided to patients can be dramatically improved, whilst overall cost savings are obtained as a result.

In addition, administrative productivity can be increased with the data exchange tool. For mandated registry data submission such as National PROMs, NJR and now BSR (Apr 2019), data is entered just once and the Amplitude pro enterprise™ platform uploads the relevant information as required, with the data being retained for local analysis.
Current and planned activity: 
With a wealth of NHS experience in the Amplitude team, the products we design and develop have NHS priorities and needs at the heart. When the pro enterprise™ platform is deployed into a hospital or trust, the Amplitude development team continue to improve the system to best service it’s users. Upgrades are released annually, upgrading the functionality on a regular basis.

CCG’s are looking at commissioning based on outcomes and lucrative contracts are sent to the trusts and hospitals with the best results. pro enterprise™ ensures boards can evidence their results to win these contracts, adding funding to budgets.

pro enterprise ™ promotes interoperability. The ability to receive data via exchange from a growing number of PAS’s is a major factor in reducing administrative workload and costs, but when this technology is combined with the ability to also push the data (electronically) to populate the associated registries too, the benefits and cost reductions are multiplied.
What is the intellectual property status of your innovation?:
Amplitude Clinical Outcomes own the intellectual property rights on this platform.
Return on Investment (£ Value): 
high
Return on Investment (Timescale): 
2 years
Ease of scalability: 
Simple
Read more
Hide details
Sarah Steptoe 16/04/2019 - 10:58 Publish Login or Register to post comments
0
0
Votes
-99999
Innovation 'Elevator Pitch':
ISL has recently developed a Clinical Trial platform that could be used for collaboration by multiple institutions including NHS/Academia/Pharma/Industry.  Shared protocols, intelligent workflows and secure data management underpin the solution.
Overview of Innovation:
Ensuring your data is accurate, your samples are viable and your results are verifiable are essential when managing clinical trials and carrying out research.

Achiever Medical provides your laboratory with the functionality to manage data quality and integrity, an audit trail to help you assess the quality of your samples and a workflow tool to help map your processes into the solution, including managing the approvals process.

  • Clinical trial functionality to allow easy adoption and customisation for launching and building up clinical trial datasets
  • Manage cohorts, studies, samples, visits and results within a single system that can be shared amongst all collaborating parties
  • One system across multiple institutes, pharma, industry and academia
  • Management reporting cross centre
  • Create and deliver trials quickly with customised data requirements
  • Enforce trial protocols to promote quality and single approach
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Long term conditions: a whole system, person-centred approach / Advanced diagnostics, genomics and precision medicine / Clinical trials and evidence / Digital health / Innovation and adoption
Benefit to NHS:
  • Rapid rollout of system to support data capture of clinical trials
  • Modify processes and protocols per clinical trial with minimal recourse to IT
  • Share data regionally/nationally across trials
  • Role based permissions to protect data
  • Single system to administer
  • Adapt processes and protocols for trials quickly
Assess Sample Viability
Ensuring you are carrying out research on viable samples is essential when validating any results.  Achiever provides a comprehensive audit trail against each sample including complete details of storage location history (with a temperature audit),  sample check out history (when, by whom, how long and for what purpose) and sample processing history (with sample collection date/time, processed date/time).  A complete sample family history is also available for managing aliquots with related samples (including parent) accessible with a single click.
 
Maintaining Confidentiality
Confidentiality is not only critical when handling patient information but is also a legal requirement.  Achiever offers flexible, secure data protection options to restrict access to identifiable and sensitive information to authorised users only.  Data encryption routines encrypt data at source whilst data security filters only allow authorised users access to selected information within the system.
 
Managing Studies and Workloads
Define studies within the Achiever system and link team members along with their relevant roles.  Generate activities to create and manage workloads with a graphical calendar available to view team schedules.  Monitor and track equipment and consumables used. Capture analyses and results along with any associated documentation and images.
Initial Review Rating
4.60 (1 ratings)
Benefit to WM population:
  • Make clinical trials available quickly to patients within the WM region
  • Ease of reporting to present efficacy of trial within the region
  • Show proactivity of centres and success in recruiting potential volunteers for trial
Current and planned activity: 
The functionality is being rolled out within a Health Trust in the East of England.  The company now wishes to find a national / regional opportunity that would benefit from a single system to promote trials.
What is the intellectual property status of your innovation?:
Released.
Return on Investment (£ Value): 
high
Return on Investment (Timescale): 
0-6 mon
Ease of scalability: 
Simple
Co-Authors:
Read more
Hide details
Sandie Shokar 30/08/2018 - 16:55 Publish 3 comments
0
0
Votes
-99999
Innovation 'Elevator Pitch':
Currently, a GP refers Obstructive Sleep Apnoea patients to an NHS Specialised Sleep Centre. Averaging 24 wks & 3-5 hospital visits before the Patient starts treatment.
Now, a GP with SOMNOtouch can receive results in 48-72Hours (3days vs. 6Mths)
Overview of Innovation:
Currently
The vast majority of patients with Obstructive Sleep Apnoea (OSA) are referred by their GP to a Specialised Sleep Centre at an NHS Hospital with a Average waiting time 12 Weeks


Patients are initially seen by a Consultant or a Sleep Physiologist who would prescribe a Diagnostic Study to be performed either in hospital or at the patient’s home. Average waiting time 12 Weeks
The patient returns to have the sleep study done or to collect the monitor and then returns the device the next day. After a further waiting time of upto 6 Weeks the patient visits the hospital again to obtain the results of the sleep study and if Positive, to discuss treatment.
A letter is sent to the GP informing them of the results and if agreed, a prescription is issued by the GP for the recommended therapy this may also take an average of 6 Weeks to arrive.
 This is prior to any treatment being administered such as a CPAP where if used they attend annually to check on compliance and progress.
 
This 6 month process is dramatically reduced by the S-Med Service to just a few days before an intervention can be delivered.


Now
The GP fits SOMNOtouch, a Combined OSA/Hypertension Monitoring Device to the patient, after 24 hours they return to the GP practice where the device is removed and the GP uploads the data from the device to a secure NHS Digital Cloud Server.
SOMNOtouch NIBP - Five devices in One
Video link: http://www.s-med.co.uk/Products#nav-product-86
 
S-Med Ltd’s Qualified and Registered Physiologists interprets the study and provides a recommendation for further treatment or investigation within 24 to 48 hours to the GP surgery. (All analysis and interpretations are supervised by a senior Consultant).
 
The report is sent to the GP who would then provide a prescription for the relevant therapy to be provided.
 
Thus within 48 to 72 hours a patient can be treated or directed for additional investigations or treatment before their condition deteriorates.

 
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Long term conditions: a whole system, person-centred approach / Advanced diagnostics, genomics and precision medicine / Wellness and prevention of illness / Wealth creation / Clinical trials and evidence / Digital health / Innovation and adoption / Patient and medicines safety / Person centred care
Benefit to NHS:
Faster response times and time to providing treatment from an average time from referral to treatment of 6 months (24 weeks) down to 4 to 5 days (1 week). With the added benefit if there are more critical underlying conditions then these may be picked up and dealt with quickly
 
Reduction in costs of patients being referred to NHS sleep centres thus less calls and pressure on such specialist clinics e.g.:
 
Reimbursement Tariffs for OSA and Hypertension
Current reimbursement guidelines from the Department of Health are:
  • For Ambulatory Sleep Diagnostic Study: £391.00
  • For 24-Hour NIBP Study: £268.00 (UCL NHS Foundation Trust, there is no NHS tariff)
  • For 24-Hour ECG Study: Recording - £268.00 plus Analysis £215.00 (UCL NHS Foundation Trust, there is no NHS tariff)
 
Cost Savings Calculation
Assuming the following:
  1. Adult Population of the England is Approx. 45 million
  2. BLF figure show approx. 10% of population suffers from OSA = 4.5 million
  3. DH figures show that approx. 30% of adult population has Hypertension = 13.5 million
  4. Public Health England shows that 1.3 million people have Atrial Fibrillation
 
The cost of referring 1% of the above population to hospital annually, will cost approximately:
  1. OSA – 45,000 £32 million per year.
  2. Hypertension – 135,000 £79 million per year
  3. AF – 13,000 £10.5 million per year
 
Total cost of £121.5 million
Cost of S-Med Service - £38.6 million
Savings to NHS = £83 million per year.
 
Aside from OSA, this equipment can be used for chronic heart conditions studies as well as more longitudinal studies adding a wealth of data for clinicians to inform them of patient’s conditions at work, rest and play without the equipment being intrusive and disturbing as current cuff based systems thereby removing the abnormal results they can provide. Thus, this equipment may also be of benefit to clinical trial units or during treatment to monitor the physiological effects experienced by patients undergoing a drug or other clinical interventions. 
Initial Review Rating
5.00 (1 ratings)
Benefit to WM population:
In addition to patients getting a faster diagnosis, it will reduce the burdens on NHS Trusts not only from the reduction on 1st line referrals to hospitals, but from patients conditions deteriorating, or suffering economic or social problems waiting 6 months for a diagnosis and treatment to be considered.

North West Innovation Agency (AHSN) will be conducting a pilot which will monitor 75 patients via a number of GP’s Practices. Results should be available by the End of February 2018.
As a West Midlands based company we would welcome an opportunity to work with NHS Trusts and CCG’s within the region to help us grow this service within the UK for the NHS and to increase our team to service and facilitate such requirements.  
Current and planned activity: 
Current NHS engagement
  • Embarking on a NIA application with North West Innovation Agency
  • Submitted an application into the ITP based on experience and adoption within the NWIA area.
  • Considering a NIHR project following a meeting at AHSN meeting - Speaking with West Midlands NIHR/CRN
Requested NHS engagement
  • Procurement / Adoption of: -  Would welcome assistance to gain greater Adoption by Trusts and CCGs within the West Midlands
     
  • Evaluation / Validation / Clinical Trial – Interested in trials for use of our ambulatory equipment (SOMNOtouch) within new clinical areas to show its versatility and extend its clinical use to provide validated evidence within in these new areas.
     
  • Project Assistance S-Med is interested in locating potential clinical / academic collaborators to engage in their current work and to explore other clinical applications of their technology.
What is the intellectual property status of your innovation?:
Device IP held by SOMNOmedics Germany. Clinical diagnostic and reporting service is owned by S-Med Ltd.
Reg. CE0494
We have obtained IGSoC Level 2 (ODS Code: 8JP12)
Return on Investment (£ Value): 
high
Return on Investment (Timescale): 
2 years
Ease of scalability: 
3
Read more
Hide details
Selwyn Sher 03/10/2017 - 13:27 Publish Login or Register to post comments
0
0
Votes
-99999
Innovation 'Elevator Pitch':
Achiever Medical LIMS helps research institutions to improve lab efficiency, facilitates return on investment into sample collections & demonstrates compliance to legislation. Inbuilt security protects patient identifiable data with controlled access
Overview of Innovation:
With increasingly stringent regulations and greater emphasis on profitability placed on laboratories, Achiever Medical LIMS was designed in conjunction with leading scientists & clinicians to provide an easy-to-use sample management system incorporating sample tracking, clinical data management, workload & communication management. The system addresses the gap left by traditional LIMS systems by providing enhanced donor and research profile data.
 
Achiever Medical LIMS is a process driven & web browser-based laboratory & clinical data management system that is flexible/scalable to evolve as needs develop. Using Open Standards to streamline the sharing of information across existing applications Achiever Medical LIMS allows data to be imported from, e.g. Patient Information & Storage Environment Management Systems, Lab equipment, Emails & Calendars for an holistic overview of samples, equipment, environment & workload.
 
Achiever Medical LIMS enables the mapping of Standard Operating Procedures (SOP) to ensure staff adhere to agreed standards, ensuring regulatory compliance & promoting quality, efficiency & consistency. Achiever Medical LIMS can assist in compliance with the Human Tissue Act, Good Laboratory Practice & CFR 21 Part 11.
 
Sample tracking functionality delivers complete traceability with automatic generation of unique reference numbers for each sample. Core sample details e.g. location/sample type are tracked as values change for a complete audit history. Sample profile information is captured including sample & tissue type, tissue collection details and associated patient & project information. Barcode labels can be generated for single/multiple samples & customised information can be contained within each label. These labels can be scanned to facilitate rapid sample retrieval.
 
Achiever Medical LIMS integrates data and processes across multiple faculties/diverse into a single solution. This enables authorised users to gain an holistic oversight, having full access to complete donor/patient records. Robust security filters and flexible tools within the LIMS allow the creation of custom levels of user security access to samples, donors or project information. This flexibility is especially useful for biobank or bio-repository management or when conducting multiple studies/clinical trials/projects with multiple collaborators. These tools support collaborative working and simplify a task that can otherwise be legislatively difficult and time-consuming.
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Advanced diagnostics, genomics and precision medicine / Clinical trials and evidence / Digital health
Benefit to NHS:
Achiever’s LIMS ability to quickly and efficiently organise samples for tracking, storage and retrieval, enables the full economic and scientific value of existing samples to be effectively realised and more efficient processing of sample requests and tests.
 
Achiever Medical LIMS enables sample aliquots to be easily generated from the parent record for complete traceability with a sample ‘family history’ view available, from both the parent & child records, allowing rapid navigation between samples within the same family.
 
Tools to enable the detailed tracking & monitoring of a sample via comprehensive sample location & check in/out auditing are provided. These include recording each time the sample is removed from its location, who checked it out and for what purpose. Samples that have been ‘checked out’ are easily identifiable and can be quickly ‘checked in’ when required along with their full audit trail information.
 
Samples used and associated stock depletion during testing or analyses are automatically flagged with Achiever Medical LIMS.
 
Composite samples such as Tissue Microarrays can be easily created within Achiever Medical LIMS, with each individual sample’s position within the composite sample recorded, any requests for removal can be easily and effectively managed.
 
External sample requests received by biobanks & bio-repositories can be managed through Achiever Medical LIMS using its built in management protocols. This facility provides staff with complete chain of custody details for each sample ((the person who requested the sample, reason for request, who approved the request & expected return date (if required) are captured)). Rejected requests are appropriately managed with reasons for rejection being recorded. Where only part of the sample is required, aliquots can be generated for the required amount along with accompanying complete family history record. Dashboards highlight samples due for return, allowing staff to monitor/chase up samples where required.
 
Achiever’s complete sample auditing & sample tracking functionality records changes by staff to core sample information. Audit trail information includes details of specific information fields changed, values pre & post change, date, time and name of the user who made the change etc. Chain of Custody details, including who checked in the sample, to whom it is checked out (where relevant), storage location, details of processing and projects included in are also captured.
Initial Review Rating
4.20 (1 ratings)
Benefit to WM population:
The West Midlands population has access to the most extensive range of specialist tests from a range of stakeholders, showcasing the potential of laboratory contributions to raise the profile of the research, clinical and diagnostic expertise of the region’s NHS laboratory staff.
 
For laboratories, biobanks and bio-repositories sample tracking & donor management capabilities are of huge importance in donor profiling, consent management, traceability, chain of custody & regulatory compliance.
 
The integration of a potentially region-wide system to manage tissue tracking across multiple teams, hospitals and sites can avoid duplication of data entry and maximise data quality while working within the IT and legislative constraints imposed by disparate working environments of the users.
 
Having sought approval for sample collection, samples need to be treated in line with SOPs and available for use in research both internally and with permitted collaborators.  Utilisation of samples is important to maximise the potential benefit from the donor and to make best use of the resources available to clinicians and researchers.  Cost recovery models allow for income generation to promote the sustainability of the biobank.
 
Improving the value of data quality enables laboratory staff and researchers to search for tissue samples from specific cohorts of donors, filtering by level of consent given by donors, allowing them to search for tissues that have not opted out of specific elements of research. This level of capability will allow biobanks and bio-repositories to service very specialist research requests, increasing value.
 
The quality of the donor, consent, storage and tissue viability data greatly increases the value of the tissues to laboratory staff and researchers. Once cleansed, Achiever Medical LIMS’s storage management capabilities help to increase levels of utilisation, reducing overhead costs per sample.
 
The ‘Achiever Medical Researcher Portal’ allows authorised collaborators to view restricted data for relevant samples.  This external view portal promotes the management of sample requests all within a single system, giving an easy means of sharing samples and the relevant data.  Automatic alerts ensure applications are managed efficiently.
 
In addition, reports and analysis providing real-time data, can be run at the touch of a button instead of valuable laboratory personnel spending days (sometimes weeks) painstakingly collating information from various spreadsheets.
Current and planned activity: 
We are a West Midlands based company wishing to work with our regional health providers.  
 
Our current users include Leeds (LTHT), Nottingham (NUH) and Cambridge (CUH) Trusts all of whom use the system to manage their research samples, donor data and to support HTA Audits.
 
Both NUH and CUH use Achiever Medical as part of their involvement with GEL.
 
Achiever Medical is being used to pioneer the data standards being promoted by UKCRC.
 
We would like to work with WMAHSN who are leading the collaboration of The West Midlands Genomic Medicine Centre (WMGMC), a partnership of 18 NHS Acute Trusts across the region, working collaboratively to help to deliver the UK 100,000 Genomes Project.   
We would welcome the opportunity to discuss any requirements for sample management and donor management, projects and disease specific systems for either single organisations or multi-institutional requirements.
What is the intellectual property status of your innovation?:
All IP is owned by Interactive Software Limited.
Return on Investment (£ Value): 
medium
Return on Investment (Timescale): 
2 years
Ease of scalability: 
Simple
Read more
Hide details
Sandie Shokar 01/08/2017 - 09:19 Publish 2 comments
0
0
Votes
-99999
Innovation 'Elevator Pitch':
A functional, digital, patient-centric, diabetes self-test system providing: self-care; patient-professional shared decisions; proactive interventions; complications prevention; data integration pan NHS provider; multi-faceted NHS costs savings.
Overview of Innovation:
awergq3wrg3w
Stage of Development:
Evaluation stage - Representative model or prototype system developed and can be effectively evaluated
WMAHSN priorities and themes addressed: 
Long term conditions: a whole system, person-centred approach / Advanced diagnostics, genomics and precision medicine / Wellness and prevention of illness / Education, training and future workforce / Wealth creation / Clinical trials and evidence / Digital health / Innovation and adoption / Patient and medicines safety / Person centred care
Benefit to NHS:
wefefgvw
Benefit to WM population:
f23ef2e
Current and planned activity: 
23rwefw
What is the intellectual property status of your innovation?:
fwergq3r5g
Return on Investment (£ Value): 
medium
Return on Investment (Timescale): 
2 years
Ease of scalability: 
Simple
Read more
Hide details
Baldev 31/10/2016 - 14:26 Archived Login or Register to post comments
0
0
Votes

Innovation 'Elevator Pitch':
BVI technology is an innovative and easy to use, mHealth service to determine the percentage and distribution of visceral fat using a mobile device (tablet) or a smart phone. 
Overview of Innovation:
The Body Volume Indicator (BVI) is a new measurement for healthcare and obesity. After eight years of successful and innovative validation from scientific collaborators around the world, BVI is now undergoing final testing prior to a full launch later in 2017.

Using 3D technology, BVI calculates risk factors associated with a person's body shape, by measuring weight and body fat distribution, with particular focus on the abdomen; the area associated with the greatest risk.

BVI is designed to be a long-term addition to the Body Mass Index (BMI); the current recognised standard for measurement of obesity. The intention is for the Body Volume Indicator to become a Body Volume Index by 2020, by which time sufficient data will have been collected globally. Using smartphone technology, BVI data can now be collected anywhere with web or internet access.

Body Volume, as an indicator of health, offers a potential long-term solution as a measure of individual health risk. 

BVI was developed in the West Midlands and collaborators have included Heartlands Hospital, Aston University, Mayo Clinic and the Medical Research Council. The application was patented in the US in 2012 and throughout Europe in 2015.


 
Current Status
In 2012 Select Research obtained exclusive use of the largest and most comprehensive collection of Body Composition Data (BCD) of visceral fat data from MRI scans in the world. This has been used to develop an App which will be used to scan/photograph lightly clothed patients and then comparing their BCD database to predict their body fat and visceral fat.
 
Further research and development is being undertaken with our current BVI (Body Volume Index) tool, to provide additional evidence and to validate the efficacy, and appropriateness of this BVI application in real-life environments. Through a ‘real-life’ project work with WMAHSN will provide clinical validation for the underpinning methodology, thus making potential users (Clinicians, patients & public) aware of the benefits (social and economic) of utilising the service.
 
Thus our current BVI application is to be incorporated into the existing patient pathways currently used by Health Exchange Health Trainers in the West Midlands.
 
NB: The application has been patented in the US in 2012 and throughout Europe in 2015 and covers all measurements of part body volume for healthcare from a 3D scan. Body fat is a part volume of the human body.

Please assist us with our 5 min Survey http://BVISurvey.SSIsurveys.com​ 
Stage of Development:
Evaluation stage - Representative model or prototype system developed and can be effectively evaluated
WMAHSN priorities and themes addressed: 
Long term conditions: a whole system, person-centred approach / Advanced diagnostics, genomics and precision medicine / Wellness and prevention of illness / Wealth creation / Clinical trials and evidence / Digital health / Innovation and adoption / Person centred care
Benefit to NHS:
Visceral fat is body fat stored within the abdominal cavity around a number of important internal organs such as the liver, pancreas, and intestines often referred to as 'active fat'. This type of fat plays a potentially dangerous role in affecting how our hormones function.

Higher amounts of visceral fat are associated with increased risks of a number of health problems.  NHS healthcare costs attributed to obesity are £5.1b p.a. and set to rise by £7.1b by 2030; The cost to the UK economy is £27b p.a. Benefits through effective intervention based on accurate visceral body fat determinations are complex but undoubtedly would lead to a reduction in the burden of obesity (diabetes, heart disease, stroke, and certain cancers), by a reduction in years lost to premature mortality and disability (DALY). NICE suggests reducing obesity of 1% would save the “NHS and local authorities around £97 million per year.” Diabetes costs the NHS over £1.5m an hour or 10% of the NHS budget for England and Wales. 

The lifetime benefits of weight loss - direct £297 and indirect £2068 estimates based on 50% compliance and 25% success.  A saving to the NHS of between £1.2m and £6.9m, and the economy of between £135m and £1620m.

Select’s BVI tool App predicts the early identification body and visceral fat & estimates via a quick, simple and non-invasive scan which provides an insight and benchmark for clinicians and their patients; just by taking two photographs of a patient. 

Therefore BVI significantly contributes to the monitoring, intervention and control processes for clinicians and other health professional to apply, so that they can tackle and halt the potential for escalation into Diabetes and CHD etc.


Particular value for patients will be that they can monitor their own progress and to improvement at home. Through recognition of the scale of their own obesity and particularly any high levels of visceral fat. The early identification of visceral fat, through this simple, quick and accurate method of measuring obesity will thus take a large step towards achieving considerable saving to the NHS and the UK economy.

The proposal for delivery of BVI is under discussion with BVI data (including BMI, Waist Circumference, and Waist to Hip Ratio automatically) stored for tracking purposes on patient records via the N3 spine. Automatic data collection through BVI of current methods saves time, money and provides new informative data on body composition for future research.
Online Discussion Rating
5.50 (2 ratings)
Initial Review Rating
5.00 (1 ratings)
Benefit to WM population:
Clinical Outcomes & Economic
In the West Midlands 65.7 per cent of people are carrying excess weight, along with 65.6 per cent of people in the East Midlands. Obesity costs the UK economy exceed £3 billion per year. In Birmingham, over 25% of the population are obese - the third highest rate in the UK. The high prevalence of obesity in adults within England show that national averages of over 40% of males overweight and more than 20% obese in the 16-75 year age range, while in women the averages are lower for the overweight classification but higher for obesity.
 
Nationally GPs make 97,000 annual referrals to weight watching programmes (WWP) and costs will reach £15.6m p.a. in 2017. A saving of £48.5 per patient might be made using the BVI App. With as low as 10% uptake, £0.5m could be saved, rising to £2.8m with a 60% uptake. Better management of weight issues with patients will have significant cost savings within the West Midlands.
 
This tool will support early detection of visceral fat and therefore allow a much more preventative and timely approach to supporting West Midlands Patients to make positive lifestyle change.
 
Environmental
The BVI App offers considerable environmental benefits in reducing the number of visits (road trips) to a surgery and specialist clinics. It will also allow people within remote and rural locations to engage in such activities.
 
Research
Additional R&D is being undertaken with the WMAHSN, to further ‘validate’ the efficacy, appropriateness and validity of the BVI application in real-life environments using the BVI App, which is being incorporated into the existing patient pathways.
 
Commercially
The adoption of this technology within the West Midlands and UK will also allow our company to grow and develop, not only with increasing its functions and capabilities but also in marketing this to a worldwide healthcare organisations and individuals as obesity is a major developed countries epidemic. 
 
There is also interest from other commercial organisations involved in weight management and associated healthcare which will further extent this products role and integration with people taking charge of their well being.

Trials
The BVI tool will be tested in 3 locations in the West Midlands with patients and GP Practices in Birmingham, Dudley and Solihull. Analysis of weight loss achieved over a period will be monitored.

Please assist us with our 5 min Survey http://BVISurvey.SSIsurveys.com​ 
Current and planned activity: 
Current BVI application is undergoing R&D and incorporation into existing patient pathways within the West Midlands via;
  • Patient Engagement - Face to face consultation, scanning of approximately 1000+ patients
  • Clinical Benefits - Analysis and monitoring of weight loss achieved over a defined period. Developing delivery protocols
  • Dissemination - Facilitation of BVI tool awareness raising sessions with Key Public Health and NHS Management, Clinical Teams and frontline staff
  • Training - BVI tool training to specialist clinical teams (Primary & Acute), ensuring correct use of the tool and providing feedback for use with patients
  • Data analysis – Verification/validation of App algorithms
  • Data gathering - Provision of clinically requested data – Core data profiling to gauge health outcomes and patient benefits. Establishing minimum data requirements
Required
  • Evaluation & Trials - Seeking trial interests
  • Adoption – Looking for discussions with CCG’s, Healthcare and Council Health Prevention teams   
What is the intellectual property status of your innovation?:
BVI has both BVI Patents and Trademarks approved.
Return on Investment (£ Value): 
Very high
Return on Investment (Timescale): 
6-12 mon
Ease of scalability: 
Simple
Regional Scalability:
We have not as yet implemented at scale within the WM region or elsewhere. The BVI product will be launched in the US market in March 2017 and Select Research Ltd are currently in discussions with Health Exchange and NHS Heartlands Hospital (who are collaborators on BVI development) for a possible follow on wider trial across the region for 2017.
Measures:
When the BVI app has been fully completed in terms of it’s scalability for widespread use, the trial results have been published and the launch takes place in April 2017, the success criteria will be determined by the number of users and the take up when the product is available and being used by customers.
 
Development is currently ongoing with scaling of the technical infrastructure for release on all accepted and recognised technical platforms (e.g. Google Play. App Store) in late April 2017. The success criteria will then become easily measurable by virtue of the volume of downloads achieved after launch.
Adoption target:
These will be dependent upon the outcome of the discussions with NHS Heartlands Hospital and Health Exchange as to a future extended trial.
Read more
Hide details
Richard Barnes 16/08/2016 - 13:59 Approved Login or Register to post comments
0
0
Votes

Innovation 'Elevator Pitch':
e-ASPECTS automates medical imaging analysis, providing confident decisions in the treatment pathway for acute stroke patients.  e-ASPECTS automatically implements the clinical scoring methodology, Alberta Stroke Programme Early CT.
Overview of Innovation:
Brainomix’s ground-breaking technology, e-ASPECTS, circumnavigates the time lag to treatment by automatically implementing the Alberta Stroke Programme Early CT Score (ASPECTS) scoring system on brain images from acute ischemic stroke patients, to identify and quantify signs of early ischemic stroke damage and provide an assessment to support treatment decisions.

Innovation of Brainomix e-ASPECTS Stroke Imaging
The key thing to note that is that the solution is highly innovative and first to market of its kind with no comparable solution available. Our co-founders include Professor Alastair Buchan, dean of medicine at Oxford University and the inventor of the ASPECTS score, and practicing clinician Professor Iris Grunwald, interventional Neuroradiologist at Southend Hospital and one of the first physicians to be successfully performing thrombectomies in the UK. 
  • e-ASPECTS is a decision support tool that automates the clinically validates ASPECT method scoring of CT scans, providing a fast, standardized result
  • e-ASPECTS is the only decision support tool for scoring non-contrast CT scans of stroke patients using the ASPECT method - a well established stroke scoring system
  • It is CE marked and has been validated to perform as well as expert Neuroradiologists in performing ASPECTS on hyper-acute stroke patient scans
  • Multiple randomized multicentre clinical trials have demonstrated (as recently as last year) that endovascular treatment is effective, and it is set to become the future standard of stroke care (in conjunction with existing thrombolysis treatments).
  • International guidelines for the selection of patients for this treatment include the ASPECTS score for identifying ischaemic core on non-contrast CT scans
 Health Economics
·         Reduced length of stay – baseline 0.04 days per patient
·         Identifies the correct treatment option for stroke patients and speeds up
          treatment times
·         Reduced decision making time for stroke patient – baseline 15 minutes per
          patient
·         Increased uptake of thrombectomy - baseline x 1.1 (i.e. 10% increase)
·         Cost savings - projected cost saving for a 15 minute time reduction in
          decision making is £40 of consultant time, plus £21 from reduced length of
          stay, leading to a total of £61 saving per patient. If thrombolysis uptake is               also increased by 20%, the total saving rises to £150 per patient.


 
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Advanced diagnostics, genomics and precision medicine / Digital health
Benefit to NHS:
Health Economics
·         Reduced length of stay – baseline 0.04 days per patient
·         Identifies the correct treatment option for stroke patients and speeds up treatment times
·         Reduced decision making time for stroke patient – baseline 15 minutes per patient
·         Increased uptake of thrombectomy - baseline x 1.1 (i.e. 10% increase)
·         Cost savings - projected cost saving for a 15 minute time reduction in decision making is £40 of consultant time,
          plus £21 from reduced length of stay, leading to a total of £61 saving per patient. If thrombolysis uptake is also
          increased by 20%, the total saving rises to £150 per patient.
Initial Review Rating
5.00 (1 ratings)
Benefit to WM population:
Better patient outcomes and treatment options.
Current and planned activity: 
We already have a number of NHS Hospitals and hospitals abroad using this solution. Once we have engaged with a Clinician who is interested in this solution we arrange to provide them with a demonstration so they understand the full benefits of the technology.
What is the intellectual property status of your innovation?:
IP is wholly owned by Brainomix. We follow a "trade secret" approach rather than patenting as we believe that this is more appropriate as it is a software device.
 
Return on Investment (£ Value): 
high
Return on Investment (Timescale): 
1 year
Ease of scalability: 
Simple
Regulatory Approvals:
Please describe any current regulatory approvals you have achieved and how they were met/ in progress/planned.
Commercial information:
Please describe how the product/service is being developed commercially, whether in development, trials, pilot or full commercial delivery. Include the results you have from any market/demand surveys and forecasts . Please include any research you have on the broader commercial opportunity for the innovation both within the health sector nationally and internationally.
Investment activity:
Please describe what stage of investment you have reached and whether you are seeking additional rounds of investment. Please include cash investment as well as investment of soft assets such as access to specialist equipment, knowledge, trial base etc. and indicate the types/sources of your investment such as grants etc.
Regional Scalability:
Please describe how the innovation could be scaled across the WM region. Have you implemented at scale in any other regions?
Measures:
What outcomes are you hoping to achieve and what are the measures that you will use to gauge the success of the innovation and how will these assessments be made? Please ensure that you have quality, safety, cost and people measures.
Adoption target:
What are the targets for adoption across the WM and what are the minimum viability levels?
Investment sought:
What investment are you looking for in order to support wider adoption of this innovation and what have you managed to secure to date? Please provide a breakdown of these costs if possible.
Read more
Hide details
Deb Whitehall 26/04/2016 - 18:26 Publish Login or Register to post comments
6
1
Votes
-99999
Innovation 'Elevator Pitch':
Proven in practice with NHS Pathology Laboratories, Pathology Manager delivers complete document management  support for all pathology process and works in partnership with any existing LIMS, PAS or Order Comms systems.
Overview of Innovation:
Complete Document Management for Pathology Departments to enable access too, and the sharing of information.
A proven scanning, barcode recognition and metadata tagging system for all paper forms used across a Pathology Department with instant retrieval & viewing from a web browser and via integration with any existing Pathology LIMS plus additional options for incorporating all other paper and digitally generated documents.
Developed in collaboration with NHS Pathology Laboratories, Pathology Manager delivers complete document management support for the whole pathology process. It enables the scanning of pathology request forms & paper documents and ingestion of digital files all into one system with intelligent barcode recognition and easy application of metadata plus instant search, retrieval & viewing directly over the organisation's network and from within an existing LIMS or PAS. It is 'plug & play' and very (very) affordable.

Uniquely with Pathology Manager, all documents - scanned paper, digitally generated (e.g. Word), emails, data reports, etc - are seen together via a Single Unified View (simultaneous viewing whatever their file type). And with instant searching, filtering and reporting plus automated alerting, auditing and monitoring, full document management across all pathology activities is ensured.

Pathology Manager works in partnership with existing LIMS (Laboratory Information Management Systems) like Clinisys MasterLab or Winpath, StarLIMS and Telepath (and any PAS) in support of all the pathology processes.

For additional information on features and benefits - Please visit:
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Advanced diagnostics, genomics and precision medicine / Wealth creation / Digital health / Innovation and adoption / Patient and medicines safety
Benefit to NHS:
Helping Pathology save costs
  • There is no limit to the number or volume of scans generated (i.e. there is no extra 'cost per image' as with most other scanning software)
  • There is no limit on the number of users
  • There is no limit to the volume of documents made available for search & retrieval
  • Instantly reduces paper storage space and improves process efficiency
  • Pathology Manager is significantly more affordable than any alternative whilst providing 'best of breed' features & functionality
Essentially, with Pathology Manager both the Cost of Purchase and the Cost of Ownership are significantly better than any alternative 

"Pathology Manager has allowed us to improve the efficiency, accuracy and speed of some of the key services provided by the Pathology Department.  It has provided a highly cost effective, high performance solution to a long standing information management challenge".   
Worcestershire NHS Pathology


For additional information on features and benefits - Please visit:
Initial Review Rating
4.20 (1 ratings)
Benefit to WM population:
  • Folding Space would like to extend the use of our software across the whole of the West Midlands as this would allow us to grow and develop not only our service here in the region but also to excelerate our software development and its facilities, products and our company.
Current and planned activity: 
  • Currently selling Pathology Manager into the NHS with adoption of the product within two trust within the West Midlands region
    • Walsall Healthcare NHS Trust
    • Worcester Health and Care NHS Trust
    • North Midlands NHS
       
  • Folding Space is working in conjunction with multiple trusts to pilot and develop a new product that will be market ready in April 2016. This project has been funded by Innovate UK
Planned / required activity
  • Increased procurement / adoption of Pathology Manager within the West Midlands region
     
  • Folding Space currently have another medical product in development that will be ready for commercialisation in April, further support and interest in the product will be sought at that time
What is the intellectual property status of your innovation?:
Folding Space owns all its IPR
Return on Investment (£ Value): 
high
Return on Investment (Timescale): 
6-12 mon
Ease of scalability: 
Simple
Regional Scalability:

Yes

Measures:

Revenues

Adoption target:

UK wide, commercial and public sector

Read more
Hide details
Chris Massey 29/02/2016 - 15:37 Detailed Submission Login or Register to post comments
3.3
3
Votes
-99999

Recent Activities

EverInspire - Wellbeing and Coaching Platform has been moved from Initial Submission to Publish 2 months 2 weeks ago
Docly enables online clinician-patient communications supported by guideline derived algorithms through text,voice, and video. has been moved from Initial Submission to Publish 2 months 2 weeks ago
SenseGuard™ - seamless monitoring of lung function for patients with respiratory conditions has been moved from Initial Submission to Publish 2 months 2 weeks ago
Bitjam: Health and social care software research and development services has been moved from Initial Submission to Publish 2 months 2 weeks ago
The Real Birth Online Workshop: addressing the barriers to effective antenatal education has been moved from Initial Submission to Publish 2 months 3 weeks ago

Active Campaigns